In addition, CAN04 is able to suppress AML and CML cell proliferation through the targeting of IL-1RAcP and subsequent blocking of IL-1 (19, 20). This evidence concerns the gene IL1A and chronic myelogenous leukemia, BCR-ABL1 positive.